Apollomics has announced two new cohorts in its global Phase 2 SPARTA study of Vebreltinib in non-small cell lung cancer and other solid tumors with MET dysregulation. The first cohort is evaluating the addition of vebreltinib to EGFR tyrosine kinase inhibitor for patients with EGFR-mutated NSCLC progressing on first line EGFR inhibitor therapy. The second cohort will evaluate vebreltinib monotherapy in histology-agnostic solid tumors with wild type MET gene that have high expression of c-MET and hepatocyte growth factor. A separate, ongoing Phase 1/2 trial is exploring the safety and efficacy of combining vebreltinib with frontline osimertinib in patients with EGFR-mutated NSCLC.